#ACR25 Clinical Preview by Prof Coates for use now: GLP-1 agonist & Diet Abstr#813 GIP/GLP-1 improved MSK pain Abstr#849 GLP-1 reduced risk of #MACE in PsA Abstr#2690 RCT = the degree of weight loss regardless specific dietary strategy determined benefit in PsA @RheumNow

A GR2 cohort study on fetal & maternal outcomes in SSc pregnancies 14/58 pts had adverse preg outcomes: pre-term, placental complications, SGA, pre-ec. Dse. worsening assoc w/ cutaneous vasc events - RFs: +anti-centromere, prior event, diffuse SSc #ACR25 @RheumNow Abs2655

Retro study on incidence of PsA in Pso pts treated w/bDMARDs IL-17i sig. ⬇️RMTL for time vs. IL-12/23i & antiTNF x 58wks Reduxn in time to PsA of IL17i: 45% vs IL23i 61% vs IL12/23i 74% vs TNFi Addtl tx benefit of IL17i ⬆️studies needed #ACR25 @RheumNow Abs2689

RCT re: effects of pre/peri-/menopause on Psa by Dr Eder et al Perimenopause ⬆️ DAPSA Fatigue - potential partial mechanism in ⬆️DAPSA Consider other factors ie perimenopause that can affect dse & tx outcomes in PsA #ACR25 @RheumNow Abs1714

Retro cohort PPACMAN: Effect of GLP-1RA on wgt, dse activity, ♥️metabolic data in PsA GLP-1RA assoc w/ wgt loss, CRP, pain, LDL, BP Degree of wgt loss proportional to ⬇️in DAPSA interesting data but larger trials needed #ACR25 @RheumNow Abs2687

DIPSA study: RCT on efficacy of diet interventions in PsA All grps: Med diet, DASH-LC & standard diet advice ⏩️ wgt loss & ⬇️dse activity (✅ DAPSA, MDA) Wt loss >>> clinical benefit than diet type Weight loss very impt, include in PsA mgt strategy #ACR25 @RheumNow Abs2690

Prospective RCT on safety & efficacy of TAC+GC vs. MMF+GC TAC+GC was comparable to MMF+GC as continuous induction maintenance treatment over 96 wks for LN. AE rates comparable. TAC - AKI & tremor MMF - leucopenia reassuring data.more tx options. #ACR25 @RheumNow Abs2697

Abs2651

This prospective study from Brazil evaluated the effect of RHZ vax in SSc pts SSc pts had ⬆️rates of seroconversion mean titers ⬆️ from BL Local rxs ⬇️ in SSc pts Systemic rxns comparable among the 2 grps interesting data. longterm studies still needed #ACR25 @RheumNow Abs2653

Dr. LRoss presents the SCTC SSc Heart Involvement classification criteria ♥️Criteria score >/= 11pts 🔸SN 77.8%; SP 95.9% 🔸OR 82.6 Huge endeavor towards standardization of SHI to help improve patient outcomes in the future 👏👏 #ACR25 @RheumNow

Fighting fire with butyrate 🔥🚒 ♦️probiotics and prebiotics Dr. Nisha Manek on inflammation and butyrate - it reduces gut inflamm thru the NFKB pathway #ACR25 @RheumNow

Day 3 Recap- ACR Convergence 2025 Highlights https://t.co/4ZiTWVVwhl The analogy used by @RheumNow to explain difference between completion versus intention to treat analysis hahahaha. You look good either ways! @bella_mehta @RHEUMarampa @EBRheum

Sex differences in 💊 d/c in axSpA from the RISE registry 🔅Females - ⬆️discontinuation risks for TNFi 🔅No sex differences seen in dc risks for IL17i and JAKis 🔅Young females discontinued faster than males Gender diff in SpA can guide tx decisions #ACR25 @RheumNow Abs2634

Cohort study comparing 3yr safety outcomes of JAKi vs. TNFi in AS pts JAKi use: ⬆️incidence of HZ infxn but not significant; ⬆️all-cause mortality (HR 4.94) and GI bleed (p=0.04) Individualize tx. consider potential complications #ACR25 @RheumNow Abs2633

Predictors of retinopathy progression after HCQ discontinued? In the chart review of 28 pt records who had retinopathy, 35% progressed despite d/c Age - significant assoc'n with progression ✳️monitor toxicity more closely esp in older pts #ACR25 @RheumNow Abs2444

Post-hoc analysis of CARE study comparing effect of Cenerimod 4mg vs. PBO Mos. 4-6: >10% improvement in alopecia w/Cenerimod Mos. 2-6: >10% improvement in mucosal ulcers w/ Cenerimod Early improvement in alopecia & ulcers w/Cenerimod Promising? #ACR25 @RheumNow Abs2440

Dr. John Stone on IgG4RD ⬆️ common in males ⬆️internal organ involvement 🔸Mimics cancer 🔸Indolence makes it dangerous —-> organ complications Diagnosis highly dependent on the rheumatologist based on clinical features, serologies, imaging & pathological data #ACR25 @Rheumnow

ROC-SpA study assessed whether changing to an IL-17Ai was superior to rotating to a 2nd TNFi in axSpA pts who failed on a 1st TNFi At wk 24, no significant diff in ASAS40 rates bet the 2 groups IL-17Ai not superior to a 2nd TNFi Rotate or change? #ACR25 @Rheumnow AbsLB09

Data from this retrospective cohort study by Alomari et al show that SLE pts on SGLT2is ⬇️rates of PulHPN (OR 0.79) ⬇️all-cause mortality (0.49) ⬇️hospitalizations (OR 0.56) ⬇️LN (OR 0.4) vs non-SGLT2i users(p<0.001) Impt role of SGLT2i as adjunct tx #ACR25 @RheumNow Abs2438

Gender differences in p/axSpA in Turkiye from ASAS-PerSpA: Males - early onset IBP (<45yrs); sacroiliitis on CR, HLA-B27+ (vs. females) Females - peripheral dse, enthesitis, Pso, dactylitis; ⬆️dse activity, FM (vs. males) Individualize & optimize tx. #ACR25 @RheumNow Abs2322